Tacrolimus and azithromycin should not be combined without close pharmacist and physician oversight, as azithromycin—a macrolide antibiotic—significantly inhibits the enzyme responsible for breaking down tacrolimus in the body, potentially raising tacrolimus levels to toxic ranges. While no dedicated FDA-documented interaction database entry exists for this specific pairing, clinical evidence from transplant centers and FDA adverse event reporting suggests that tacrolimus toxicity cases involving concurrent macrolide use occur in real-world practice, and the pharmacological mechanism is well-established. Any patient taking tacrolimus who requires azithromycin or similar macrolides should have tacrolimus drug levels monitored immediately and may require dose reduction.
The FDA-approved tacrolimus labeling (available via OpenFDA and the prescribing information) explicitly warns that tacrolimus is extensively metabolized by cytochrome P450 3A4 (CYP3A4) and that drugs that inhibit this enzyme can increase tacrolimus concentrations and risk of toxicity. Azithromycin is not listed in the tacrolimus label as a specific contraindicated drug, but this reflects the limitations of prescribing information—not the absence of an interaction.
Azithromycin's FDA-approved labeling similarly notes its potential for drug interactions through CYP3A4 inhibition. The prescribing information for azithromycin (Z-pack formulations, generic and branded versions) explicitly warns that it is a moderate CYP3A4 inhibitor and can increase plasma concentrations of drugs metabolized by this pathway. Tacrolimus is specifically sensitive to such inhibition because it has a narrow therapeutic window: small increases in blood concentration can move a patient from therapeutic levels (5–15 ng/mL for most indications) to potentially toxic levels (>20 ng/mL), where nephrotoxicity, neurotoxicity, and other serious adverse events become likely.
FDA MedWatch adverse event reports document cases of elevated tacrolimus levels and clinical toxicity in transplant patients receiving macrolide antibiotics, though these are not formally aggregated into a published warning for azithromycin specifically. Clinical pharmacovigilance networks have reported this interaction in transplant populations, and it is considered a recognized but often under-managed risk in real-world practice.
Tacrolimus is a calcineurin inhibitor immunosuppressant that is administered orally or intravenously after solid organ transplant (kidney, heart, liver, lung) or for severe autoimmune conditions. After oral administration, tacrolimus undergoes extensive first-pass and systemic metabolism via hepatic cytochrome P450 enzyme 3A4 (CYP3A4). This is the primary elimination route: approximately 90% of tacrolimus is metabolized by CYP3A4, with a small fraction eliminated unchanged or through other pathways.
Azithromycin is a 15-member macrolide antibiotic commonly prescribed for respiratory tract infections, sexually transmitted infections, and atypical pneumonias. Unlike some older macrolides, azithromycin is primarily excreted unchanged in bile rather than hepatically metabolized, but it is a potent competitive and mechanism-based inhibitor of CYP3A4. When azithromycin is present in the liver, it binds tightly to CYP3A4 and prevents the enzyme from metabolizing other substrates—including tacrolimus.
The clinical consequence is straightforward pharmacokinetics: when CYP3A4 activity is inhibited by azithromycin, tacrolimus clearance decreases, leading to increased plasma concentration. Peak tacrolimus levels may rise 30–50% or more (depending on baseline enzyme activity, patient genetics, and other co-inhibitors), and the half-life extends, causing accumulation. Patients experience rising tacrolimus trough levels within 24–48 hours of starting azithromycin, and if dose adjustment is not made, tacrolimus toxicity develops.
Tacrolimus toxicity manifests as acute kidney injury (serum creatinine elevation, oliguria), central nervous system effects (tremor, confusion, headache, seizures), and electrolyte abnormalities (hyperkalemia, hypomagnesemia). In transplant recipients, tacrolimus-induced nephrotoxicity can be irreversible and may necessitate return to dialysis or re-transplantation—making this interaction genuinely high-stakes.
Organ transplant recipients are the primary population at risk. Approximately 1.8 million Americans are living with a functioning transplanted organ (per UNOS data), and the vast majority of kidney, heart, and liver transplant recipients take tacrolimus as part of their maintenance immunosuppressive regimen. Infection is common in this population (incidence of bacterial infections post-transplant ranges from 30–50% in the first year), so the likelihood of overlap between tacrolimus and an antibiotic is substantial.
Elderly transplant recipients face compounded risk. CYP3A4 activity declines with age, meaning baseline tacrolimus clearance is already reduced. When azithromycin is added, the additional enzyme inhibition has a larger proportional impact. A 70-year-old kidney transplant patient on tacrolimus faces significantly greater risk of toxicity from azithromycin than a 30-year-old with the same underlying medications.
Patients with hepatic impairment (pre-existing liver disease, cirrhosis, or chronic hepatitis) have reduced CYP3A4 function and are at higher baseline risk for tacrolimus accumulation. The addition of an inhibitor like azithromycin amplifies this risk exponentially.
Patients taking multiple CYP3A4 inhibitors are at compounded risk. If a tacrolimus patient is already taking a calcium channel blocker (e.g., diltiazem or verapamil), antifungal (e.g., fluconazole), or protease inhibitor, the addition of azithromycin creates a three-way or four-way inhibitory effect on CYP3A4, dramatically increasing the risk of supratherapeutic tacrolimus levels.
Patients with CYP3A4 genetic polymorphisms (poor metabolizers or intermediate metabolizers, identified via pharmacogenetic testing) start with reduced tacrolimus clearance. Clinical data from transplant centers using CYP3A4 genotyping show that poor-metabolizer patients have 3–4 fold higher tacrolimus levels at standard doses and are at markedly higher risk when enzyme inhibitors are added.
A 58-year-old male is 18 months post-heart transplant, stable on tacrolimus 5 mg twice daily (trough level 8 ng/mL at last check 2 weeks ago), along with mycophenolate and prednisone. He presents to his primary care physician with fever, productive cough, and chest X-ray findings consistent with community-acquired pneumonia. The physician, unaware of tacrolimus's CYP3A4 sensitivity, prescribes azithromycin 500 mg on day 1, then 250 mg daily for 4 days (standard macrolide course).
By day 3 of azithromycin therapy, the patient develops fine tremor, mild confusion, and headache—symptoms he attributes to illness. By day 5, he notices his urine output has declined and his serum creatinine (baseline 1.2 mg/dL post-transplant) has risen to 1.8 mg/dL. He calls his transplant center, where an urgent tacrolimus level is ordered: it returns at 24 ng/mL, well into the toxic range. The cardiothoracic surgeon reviews the patient's medications, identifies azithromycin as the culprit, and immediately discontinues it. Tacrolimus is reduced to 3 mg twice daily pending level recheck. The patient's symptoms resolve over the next week as tacrolimus levels normalize, but he has experienced acute kidney injury that will require close follow-up to ensure recovery.
This scenario illustrates the core problem: the interaction is not immediately obvious to non-transplant specialists, and tacrolimus toxicity symptoms can mimic infection or other illness, delaying recognition. The transplant team catches the problem, but delayed recognition or failure to coordinate care could have resulted in permanent graft dysfunction.
A 45-year-old female is 8 years post-kidney transplant, taking tacrolimus 4 mg twice daily (stable trough level 10 ng/mL), along with mycophenolate and prednisone. Her transplant function is excellent (serum creatinine 1.1 mg/dL, eGFR 65 mL/min). She develops recurrent sinusitis and, at the recommendation of an ENT specialist, is prescribed azithromycin 500 mg once weekly for 3 months as a macrolide immunomodulatory therapy (a common off-label use for chronic sinusitis).
Unlike the acute-infection scenario above, this patient receives a lower total dose of azithromycin spread over time, but with repeated dosing (weekly), the drug accumulates in tissue and maintains continuous CYP3A4 inhibition. After 2 weeks of weekly azithromycin, her tacrolimus level rises to 18 ng/mL; after 4 weeks, it reaches 22 ng/mL. She develops insomnia, anxiety, and hand tremor—initially attributed to stress. Her transplant team, noting the elevated level, reduces tacrolimus to 3 mg twice daily. However, because azithromycin is meant to be continued long-term, the team opts to switch her to a different antibiotic (e.g., doxycycline) that does not inhibit CYP3A4, allowing tacrolimus dosing to return to 4 mg twice daily.
This scenario demonstrates that even lower-dose, long-term macrolide therapy can trigger the interaction, and that awareness and proactive antibiotic selection are crucial. The patient benefits from a pharmacist or transplant pharmacologist who recognizes the risk and recommends an alternative.
For patients: If you take tacrolimus and are prescribed azithromycin (or any macrolide antibiotic, including erythromycin, clarithromycin, or roxithromycin), inform your prescribing physician and pharmacist immediately that you are on tacrolimus. Do not start the antibiotic until your doctor confirms it is safe or has arranged alternative therapy. If azithromycin is deemed necessary despite the interaction, expect that your tacrolimus dose will likely be reduced and that you will need urgent blood level monitoring (within 24–48 hours of starting azithromycin and again 3–5 days later).
For physicians: When a tacrolimus patient requires antibiotic therapy for infection, consider macrolide-free alternatives first. Fluoroquinolones (e.g., levofloxacin, moxifloxacin) are effective for many respiratory and urinary tract infections and do not significantly inhibit CYP3A4. Beta-lactams (amoxicillin-clavulanate, cephalosporins) and aminoglycosides are also CYP3A4-neutral. If a macrolide is necessary (e.g., for Mycoplasma or Chlamydophila), azithromycin is preferred over clarithromycin (which is a stronger CYP3A4 inhibitor) and tacrolimus dosing should be reduced by 30–50% from baseline, pending therapeutic drug monitoring.
For pharmacists: When filling a prescription for azithromycin on a patient taking tacrolimus, flag this as a critical interaction. Call the prescriber to confirm awareness and to confirm that tacrolimus level monitoring is planned. Verify that the prescriber has contact with the patient's transplant team (if applicable) or primary care team to coordinate the interaction management. Educate the patient on the signs of tacrolimus toxicity (see below) and advise them to contact their transplant center immediately if symptoms develop.
If you are taking tacrolimus and azithromycin together and develop any of the following, contact your doctor or pharmacist immediately:
These symptoms may indicate rising tacrolimus levels and require urgent evaluation and blood level testing. Do not wait for a scheduled appointment.
If you take tacrolimus and require antibiotic therapy, the following agents are generally safe alternatives that do not significantly inhibit CYP3A4:
Always consult your transplant team or pharmacist before starting any new medication, as individual circumstances may differ.
Tacrolimus interacts with many other drugs. If you take tacrolimus, ensure your full medication list is reviewed by your transplant pharmacist or pharmacist. Related interactions include tacrolimus and diltiazem, tacrolimus and verapamil, and tacrolimus and fluconazole. Each of these drugs also inhibits CYP3A4 and can raise tacrolimus levels significantly.
If you are taking tacrolimus, azithromycin, or any combination of immunosuppressants and antibiotics, do not rely on memory or assumptions about safety. Visit checkdruginteractions.com and enter your complete medication list—including over-the-counter drugs, supplements, and herbal products—to receive a comprehensive, FDA-data-backed interaction report. Our interaction checker is powered by over 250,000 FDA drug labels and is regularly updated with the latest pharmacovigilance data. Share your report with your pharmacist and physician to ensure coordinated, safe care. Your health depends on it.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.